iCo Therapeutics Inc.

iCo Therapeutics Inc. Announces the Issuance of 41,200,000 Units Pursuant to its Non-Brokered Private Placement

iCo Therapeutics Provides Corporate Update

iCo Therapeutics Announces AGM Voting Results

iCo Therapeutics Announces First Quarter 2019 Financial Results

iCo Therapeutics Announces 2018 Year End Financial Results

iCo Therapeutics Inc. Announces the Issuance of 14,400,000 Units Pursuant to its C$1,250,000 Non-Brokered Private Placement

iCo Therapeutics Inc. Announces Upsizing of Non-Brokered Private Placement to $1,250,000 CDN

iCo Therapeutics Inc. Announces the Issuance of 4,000,000 Units Pursuant to its C$750,000 Non-Brokered Private Placement

iCo Therapeutics Inc. Announces Non-Brokered Private Placement to Raise C$750,000

iCo Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Update

iCo Therapeutics Provides Corporate Update, Including Drug Supply for Next Oral Amphotericin B Efficacy Study

iCo Therapeutics Announces Oral Amphotericin B Clinical Advisory Board

iCo Therapeutics Provides Corporate Update

iCo Therapeutics Announces Additional Positive Pharmacokinetic Results and Presentation at Global Investment Conference

iCo Therapeutics Announces Second Quarter 2018 Financial Results And Corporate Update

iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials – Phase 1 Oral Amphotericin B

iCo Therapeutics Announces Positive Clinical Outcome – Primary Endpoint Met in Phase 1 Oral Amphotericin B Study

iCo Therapeutics Provides Corporate Update, Announces Completion of Phase 1 Recruitment

iCo Therapeutics Announces First Quarter 2018 Financial Results And Update On Phase 1 Clinical Trial

iCo Therapeutics Announces Year End 2017 Financial Results

iCo Therapeutics Announces Major Milestone – Dosing of First Patient for its Oral Amphotericin B Phase 1 Clinical Study

iCo Therapeutics Announces Ethics Approval for its Oral Amphotericin B Phase 1 Clinical Study

iCo Therapeutics Announces Upcoming Presentations and Meetings

iCo Therapeutics Announces Second Quarter 2017 Financial Results

iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset

iCo Therapeutics Announces Positive Oral Amphotericin Study

iCo Therapeutics Provides Multiple Corporate Updates

CLARIFICATION: iCo Therapeutics Announces Positive Study Results and Significant Advances related to Oral Amphotericin B Program

iCo Therapeutics Announces Positive Study Results and Significant Advances Related to Oral Amphotericin B Program

iCo Therapeutics Announces Third Quarter 2016 Financial Results